• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

cafead

Administrator
Staff member
  • cafead   Jun 07, 2021 at 09:12: PM
via As if the saga of aducanumab needed another twist, the Food and Drug Administration tossed in an extra curveball Monday as it approved the Alzheimer’s therapy by specifying who would be eligible for the treatment.

article source